Possible involvement of erythropoietin in remote renal preconditioning- induced cardioprotection in rats

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 2, 2008, Pages 126-130

  Diwan, Vishal ^a   Jaggi, Amteshwar Singh ^a   Singh, Manjeet ^a   Singh, Nirmal ^a   Singh, Dhandeep ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Cardioprotection; Erythropoietin; Remote renal preconditioning; Renal failure

Indexed keywords

CREATINE KINASE; ERYTHROPOIETIN; GENTAMICIN; HUMORAL ANTIBODY; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; FLOW RATE; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; REPERFUSION;

ANALYSIS OF VARIANCE; ANIMALS; CORONARY CIRCULATION; CREATINE KINASE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GENTAMICINS; ISCHEMIC PRECONDITIONING; KIDNEY; KIDNEY FAILURE; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, WISTAR;

EID: 39749140992     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31815d88c9     Document Type: Article

References (38)

1. Przyklenk K, Baurer B, Ovize M, et al. Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87:893-899.
2. Singh M, Sharma A. Mechanism of cardioprotective effect of remote aortic preconditioning. In: Dhalla NS, Angel RA, Pierce GN, eds. Pathophysiology of Cardiovascular Diseases. Boston: Kluwer Academic Publishers, 2004:277-285.
3. Tokuno S, Hinokiyama K, Tokuno K, et al. Spontaneous ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to ischemia. Arterioscler Thromb Vasc Biol. 2002;22:995-991.
4. Patel HH, Moore J, Hsu AK, et al. Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol. 2002;34:1317-1313.
5. Wang YP, Xu H, Mizoguchi K, et al. Intestinal ischemia induces late preconditioning against myocardial infarction: a role for inducible nitric oxide synthase. Cardiovasc Res. 2001;9:391-398.
6. McClahan TB, Nao BS, Wolke LJ, et al. Brief renal occlusion and reperfusion reduces myocardial infarct size in rabbits. FASEB J. 1993;7:A118-A123.
7. Skyschally A, Schulz R, Gres P, et al. Attenuation of ischemic preconditioning in pigs by scavenging of free radicals with ascorbic acid. Am J Physiol. 2003;284:H698-H703.
8. Xia Z, Herijgers P, Nishida TS, et al. Remote preconditioning lessens the deterioration of pulmonary function after repeated coronary artery occlusion and reperfusion in sheep. Can J Anaesth. 2003;50:481-488.
9. Schott RJ, Rohmann S, Braun ER, et al. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res. 1990;66:1133-1142.
10. Liauw SK, Rubin BB, Lindsay TF, et al. Sequential ischemia/reperfusion results in contralateral skeletal muscle salvage. Am J Physiol. 1996;270:H1407-H1413.
11. Loukogeorgakis SP, Donald A, Charakida M, et al. Remote ischemic preconditioning provides early and late protection against endothelial ischemia reperfusion injury in humans. J Am Coll Cardiol. 2005;46:450-456.
12. Wang YP, Maeta H, Mizoguchi K, et al. Intestinal ischemia preconditioning myocardium: role of protein kinase C and mitochondrial KATP channel. Cardiovasc Res. 2002;55:576-572.
13. Singh D, Chopra K. Evidence of the role of angiotensin AT (1) receptors in remote renal preconditioning of myocardium. Methods Find Exp Clin Pharmacol. 2004;26:117-122.
14. Weinbrenner C, Schulze F, Sarvary L, et al. Remote preconditioning by infra renal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in the rat heart. Cardiovasc Res. 2004;61:591-599.
15. Chen X, Wang J, Bai T. Myocardial protection by remote preconditioning the role of nitric oxide and neurogenic pathway. Anesthesiology. 2005;103:533.
16. Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Res. 2004;1000:19-31.
17. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003;228:1-14.
18. Daghman NA, Elder GE, Savage GA, et al. Erythropoietin production: evidence for multiple oxygen sensing pathways. Ann Hematol. 1999;78:275-278.
19. Kaelin WG Jr. How oxygen makes its presence felt. Genes Dev. 2002;16:1441-1445.
20. Lewis LD. Preclinical and clinical studies: a preview of potential future applications of erythropoietic agents. Semin Hematol. 2004;41:17-25.
21. Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nature Clin Pract Oncol. 2006;3:152-164.
22. Sola A, Rogido M, Lee BH, et al. Erythropoietin after focal cerebral ischemia activates the janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res. 2005;57:481-487.
23. Locatelli F, Alijama P, Barany P, et al. European best practice guidelines group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19:1-47.
24. Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA. 2004;101:823-828.
25. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:207-212.
26. Joyeux-Faure M, Ramond P, Begam PC, et al. Early pharmacological preconditioning by erythropoietin mediated by inducible NOS and mitochondrial ATP-dependent potassium channels in the rat heart. Fund Clin Pharmacol. 2006;20:51-56.
27. Langendorff O. Untersuchungen amuber lebenderer saugethierherzen. Pfluger Arch Gesmate Physiol. 1885;61:291-232.
28. Chopra K, Singh M, Kaul N, et al. Decrease of myocardial infarct size with desferrioxamine: Possible role of oxygen free radicals in its ameliorative effect. Mol Cell Bio Chem. 1992;113:71-76.
29. King JA. A routine method for estimation of lactate dehydrogenase activity. J Med Lab Tech. 1959;16:265-272.
30. Swanson JR, Wilkinson JH. Measurements of creatine kinase in serum. Stand Methds Clin Chem. 1972;7:33.
31. Mukundan H, Resta TC, Kanagy NL.17-Estradiol decreases hypoxic induction of erythropoietin gene expression. Am J Physiol. 2002;283:R496-R504.
32. Müllenheim J, Molojavyi A, Preckel B, et al. Thiopentone does not block ischemic preconditioning in the isolated rat heart. Can J Anesth. 2001;48:784-789.
33. Egrie JC. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 1986;172:213-214.
34. Iraz M, Sahin S, Olmez E, et al. Effects of ACE inhibition and AT1 receptor blockade on cardiac ischemia-reperfusion induced mortality and cardiac markers in rats. Turk J Med Sci. 2005;35:371-377.
35. Sharma A, Singh M. Protein kinase C activation and cardioprotective effect of preconditioning with oxidative stress in isolated rat heart. J Mol Cell Biochem. 2001;219:1-6.
36. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protect the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 2005;100:397-403.
37. Moon C, Krawczyk M, Paik D, et al. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther. 2005;19:243-250.
38. Stefanovic V, Vlahovic P, Savic V, et al. Kidney ectopeptidases in gentamicin and mercuric chloride-induced acute renal failure. Cell Physiol Biochem. 1998;8:278-284.